Former Siemens exec buys stake in Deerfield Imaging; Transcend settles Glaukos patent dispute;

@FierceMedDev: Smith & Nephew to buy robotic surgical partner Blue Belt for $275M. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. Article | Follow @VarunSaxena2

@EmilyWFierce: It seemed like things couldn't get much worse for Theranos. And then, they did. More | Follow @EmilyWFierce

> Dr. Gregory Sorensen, the former president and CEO of Siemens Healthcare North America, will take a minority interest in Deerfield Imaging and become its executive chairman. The company was created in August with the acquisition of Imris image-guided therapy assets out of bankruptcy. More

> Glaukos ($GKOS) has settled with Transcend Medical over patent infringement allegations concerning Transcend's CyPass Micro-Stent devices, appliers and delivery systems, which is not FDA approved. Transcend has agreed to make payments to equal to Glaukos of 1% of any future net sales of CyPass devices up to $6 million in total until April 2022. More

> Medtronic ($MDT) will be able to appeal a decision against it in a patent discute with Florida licensor Atlas IP. Story

Biotech News

@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Something tells me that the Pfizer/Allergan merger will inspire Ian Read to name the new company... Pfizer. | Follow @JohnCFierce

@DamianFierce: "I hope Bill Ackman has done more research on Valeant than he did on Herbalife, Target, Borders and JC Penny." Statement | Follow @DamianFierce

> AstraZeneca's olaparib looks promising among a targeted set of prostate cancer patients. More

> With a new FDA nod, Novartis enters a crowded COPD field. Story

> Sanofi dumps a $663M MS deal with India's Glenmark. Article

> José Almeida, former Covidien CEO, to head Baxter. Chutes and Ladders

Pharma News

@FiercePharma: Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott. Report | Follow @FiercePharma

@EricPFierce: Will Sanofi problems with auto injectors be its auto ejector from the epinephrine market? More | Follow @EricPFierce

@CarlyHFierce: "Pfallergan" - definitely the worst portmanteau I've ever seen for anything, ever. | Follow @CarlyHFierce

> Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott. Report

> Patent challenger Bass wins IP reviews for Celgene, Shire meds. Article

> Mylan beats Street's estimates with Q3 earnings and beats Perrigo in effort to derail tender. Item